Eli Lilly stock surges 6% after Q2 earnings beat driven by Mounjaro, Zepbound
Eli Lilly stock LLY gained 6% on Wednesday after delivering a stronger-than-expected second quarter as robust demand for its blockbuster GLP-1 medicines Mounjaro and Zepbound lifted revenue and profit well above Wall Street expectations. This has prompted the drugmaker to raise its full-year revenue outlook. The company reported adjusted earnings per share of $8.38, comfortably
